Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Trans R Soc Trop Med Hyg ; 113(11): 693-700, 2019 11 01.
Artigo em Inglês | MEDLINE | ID: mdl-31369106

RESUMO

BACKGROUND: Malaria control efforts in Sudan rely heavily on case management. In 2004, health authorities adopted artemisinin-based combination therapies (ACTs) for the treatment of uncomplicated malaria. However, some recent surveys have reported ACT failure and a prevalent irrational malaria treatment practice. Here we examine whether the widespread use of ACT and failure to adhere to national guidelines have led to the evolution of drug resistance genes. METHODS: We genotyped known drug resistance markers (Pfcrt, Pfmdr-1, Pfdhfr, Pfdhps, Pfk13 propeller) and their flanking microsatellites among Plasmodium falciparum isolates obtained between 2009 and 2016 in different geographical regions in Sudan. Data were then compared with published findings pre-ACT (1992-2003). RESULTS: A high prevalence of Pfcrt76T, Pfmdr-1-86Y, Pfdhfr51I, Pfdhfr108N, Pfdhps37G was observed in all regions, while no Pfk13 mutations were detected. Compared with pre-ACT data, Pfcrt-76T and Pfmdr-1-86Y have decayed, while Pfdhfr-51I, Pfdhfr-108N and Pfdhps-437G strengthened. Haplotypes Pfcrt-CVIET, Pfmdr-1-NFSND/YFSND, Pfdhfr-ICNI and Pfdhps-SGKAA predominated in all sites. Microsatellites flanking drug resistance genes showed lower diversity than neutral ones, signifying high ACT pressure/selection. CONCLUSIONS: Evaluation of P. falciparum drug resistance genes in Sudan matches the drug deployment pattern. Regular monitoring of these genes, coupled with clinical response, should be considered to combat the spread of ACT resistance.


Assuntos
Antimaláricos/uso terapêutico , DNA de Protozoário/genética , Resistência a Medicamentos/genética , Quimioterapia Combinada , Malária Falciparum/tratamento farmacológico , Plasmodium falciparum/genética , Proteínas de Protozoários/genética , Amodiaquina/uso terapêutico , Artemeter/uso terapêutico , Artemisininas/uso terapêutico , Artesunato/uso terapêutico , Cloroquina/uso terapêutico , Marcadores Genéticos , Genótipo , Humanos , Lumefantrina/uso terapêutico , Mutação , Polimorfismo Genético , Pirimetamina/uso terapêutico , Sudão , Sulfadoxina/uso terapêutico
2.
Sultan Qaboos Univ Med J ; 14(3): e388-92, 2014 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-25097776

RESUMO

OBJECTIVES: The aim of this retrospective study was to investigate the prevalence and pattern of third molar impaction in patients between 19-26 years old attending Sultan Qaboos University Hospital (SQUH) in Muscat, Oman. METHODS: The study reviewed 1,000 orthopantomograms (OPGs) of patients attending the Oral Health Department of SQUH between October 2010 and April 2011. Patients were evaluated to determine the prevalence of third molar impaction, angulation, level of eruption and associated pathological conditions. RESULTS: Of the study population, 543 (54.3%) OPGs showed at least one impacted third molar. The total number of impacted molars was 1,128. The most common number of impacted third molars was two (41%). The most common angulation of impaction in the mandible was the mesioangular (35%) and the most common level of impaction in the mandible was level A. Of the 388 bilateral occurrences of impacted third molars, 377 were in the mandible. There was no significant difference in the frequency of impaction between the right and left sides of both jaws. Pathological conditions associated with impacted lower third molars were found in 18%, of which 14% were associated with a radiographic radiolucency of more than 2.5 mm, and 4% of impacted lower third molars were associated with dental caries. CONCLUSION: This study found that more than half of Omani adult patients ranging in age from 19-26 years had at least one impacted third molar.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...